Circulogene Announces Four Abstracts Accepted for ASCO 2016 Conference
Research involving Circulogene’s single-drop-volume liquid biopsy
assays for real-time monitoring of cancer mutations included in ASCO 2016
BIRMINGHAM, Ala.–(BUSINESS WIRE)–#ASCO16—Circulogene
Theranostics, the only biotechnology company able to enrich
circulating cell-free DNA (cfDNA) from single-drop volumes of fluid,
today announced the acceptance of four of its scientific abstracts for
the upcoming American Society of Clinical Oncology (ASCO)
2016 Annual Meeting.
“We’re looking forward to presenting and publishing this new research,
which demonstrates the clinical validity of our assays using just
microliters of blood or other bodily fluids,” said Circulogene Chief
Scientific Officer Chen-Hsiung Yeh, Ph.D. “Our test’s ability to provide
highly sensitive and specific information on cancer gene mutation
analysis that can impact personalized treatment decision making
continues to greatly interest the medical community.”
The four abstracts accepted include the poster presentation “Circulating
cell-free DNA: The future of personalized medicine in ovarian cancer
management.” Abstracts accepted for publication only include:
-
Abstract No. e23189 “Massively parallel sequencing of cell-free DNA
enriched from a single drop of urine” -
Abstract No. e13108 “Correlation of mutation status between tissue and
blood-drop liquid biopsies from ovarian cancer patients following
chemotherapy” -
Abstract No. e16579 “Circulating cell-free DNA profiling for
potentially actionable targets in metastatic castration resistant
prostate cancer (mCRPC) using next-generation sequencing on droplet
volumes of plasma”
Full-text versions of the publish-only abstracts are available on www.asco.org
and jco.ascopubs.org
in a fully searchable format.
“We are excited to collaborate with Circulogene and use their liquid
biopsy DNA enrichment method and Next Generation Sequencing technique
for this ground-breaking research looking at the correlation between
tissue and blood biopsies in both pre- and post-chemotherapy in ovarian
cancer patients,” said Rebecca C. Arend, M.D., Assistant Professor,
University of Alabama – Birmingham.
Circulogene representatives will be on-hand during the conference at booth
No. 13104 to answer questions about the science presented and the
company’s pioneering work in liquid biopsy development.
Circulogene continues to collaborate with other biotechnology research
institutions on additional research projects. Circulogene is the first
and only biotechnology company able to enrich circulating cell-free DNA
from a single blood drop for patient-specific monitoring of cancer,
achieving maximal output from minimal input. The company currently
provides testing for breast, colorectal, lung, gastric, gastrointestinal
stromal (GIST), hematological, melanoma, ovarian, pancreatic and thyroid
cancers.
Circulogene is Clinical Laboratory Improvement Amendments (CLIA)
certified and is continuing research initiatives to independently
demonstrate greatly increased sensitivity and specificity compared to
current methods. For more information, visit our website,
connect with us on LinkedIn,
email us at info@circulogene.com
or call 855-614-7083.
About Circulogene Theranostics
Headquartered in Birmingham, Ala., Circulogene Theranostics is an
innovative molecular diagnostics company founded and operated by a team
of experienced industry executives and skilled molecular diagnostics
scientists. Applying its proprietary laboratory developed test for cfDNA
liquid biopsies, Circulogene has developed the first droplet-volume,
next-generation sequencing (NGS) method to provide full genomic load
analysis, enabling more accurate data to help clinicians and their
patients. For more information, visit www.circulogene.com
or call 855-614-7083.
Contacts
Media Contact
Armada Medical Marketing
Dan Snyders,
303-623-1190 ext. 230
dan@armadamedical.com
or
Company
Contact
Circulogene Theranostics
Scott Rezek,
205-278-1607
srezek@Circulogene.com
